Last 48 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -75.77 | — | — | 394.32 | 120.18 | — | 206.00 | 94.86 | 162.83 | 63.94 | 319.05 | 67.10 | 13.03 | 25.96 | 47.38 | 37.90 | 25.89 | 22.48 | 47.55 | 39.21 | 41.95 |
| — | — | — | +315.7% | -26.2% | — | -35.4% | +41.4% | +1149.8% | +146.3% | +573.3% | +77.0% | -49.7% | +15.5% | -0.3% | -3.3% | -38.3% | -34.4% | -4.9% | -9.7% | +39.5% | |
| P/S Ratio | 2.66 | 2.82 | 2.73 | 1.67 | 1.84 | 1.43 | 1.96 | 1.98 | 2.27 | 3.04 | 2.95 | 4.75 | 3.14 | 3.09 | 4.00 | 4.25 | 3.57 | 3.09 | 3.99 | 4.09 | 4.68 |
| — | +97.1% | +39.4% | -15.3% | -19.2% | -52.8% | -33.5% | -58.3% | -27.6% | -1.7% | -26.3% | +11.8% | -12.0% | +0.1% | +0.2% | +3.8% | -23.8% | -37.0% | -21.5% | -7.8% | +41.1% | |
| P/B Ratio | 3.71 | 4.21 | 3.79 | 2.20 | 2.86 | 1.98 | 3.35 | 3.42 | 4.91 | 5.70 | 5.18 | 9.45 | 7.59 | 7.38 | 8.73 | 9.71 | 8.93 | 8.27 | 9.49 | 9.38 | 11.80 |
| — | +113.0% | +13.1% | -35.7% | -41.7% | -65.3% | -35.3% | -63.7% | -35.3% | -22.8% | -40.7% | -2.7% | -15.0% | -10.8% | -8.0% | +3.5% | -24.3% | -24.5% | -17.0% | -6.5% | +38.0% | |
| P/FCF | 38.14 | 25.53 | — | 29.34 | 8.67 | — | — | 40.64 | 14.53 | 452.46 | — | 8566.15 | 15.41 | 133.38 | — | 46.55 | 18.46 | 167.05 | — | 41.39 | 29.03 |
| — | — | — | -27.8% | -40.3% | — | — | -99.5% | -5.7% | +239.2% | — | +18303.2% | -16.5% | -20.2% | — | +12.5% | -36.4% | -57.4% | — | +23.2% | +143.0% | |
| EV / EBITDA | 76.08 | — | — | 17.07 | 13.14 | 18.32 | 31.59 | 25.15 | 21.94 | 26.80 | 30.93 | 37.26 | 20.63 | 16.60 | 25.84 | 20.75 | 17.26 | 13.52 | 25.82 | 21.44 | 21.18 |
| — | — | — | -32.1% | -40.1% | -31.6% | +2.1% | -32.5% | +6.4% | +61.4% | +19.7% | +79.6% | +19.6% | +22.7% | +0.1% | -3.2% | -18.5% | -39.9% | -6.5% | -4.2% | +47.8% | |
| EV / EBIT | 46.94 | — | — | 58.01 | 28.11 | — | 132.61 | 54.12 | 38.26 | 47.71 | 72.88 | 48.40 | 11.84 | 20.38 | 35.59 | 26.95 | 19.75 | 16.27 | 28.81 | 24.87 | 27.45 |
| — | — | — | +7.2% | -26.5% | — | +82.0% | +11.8% | +223.1% | +134.1% | +104.8% | +79.6% | -40.0% | +25.3% | +23.5% | +8.4% | -28.1% | -38.6% | -12.8% | -7.9% | +39.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 49.1% | 49.6% | 47.3% | 46.0% | 44.1% | 44.9% | 48.8% | 50.4% | 48.4% | 48.0% | 48.9% | 50.4% | 51.5% | 49.9% | 52.5% | 51.6% | 52.4% | 50.9% | 51.5% | 50.3% |
| — | +11.4% | +10.5% | -3.1% | -8.7% | -9.0% | -6.6% | -0.1% | +0.0% | -6.0% | -3.8% | -6.9% | -2.5% | -1.7% | -1.9% | +1.9% | +2.7% | +3.4% | +3.4% | +2.2% | -0.0% | |
| Operating Margin | 6.9% | -10.4% | -7.8% | 5.5% | 11.4% | 4.1% | 1.5% | 4.0% | 7.4% | 7.9% | 6.0% | 9.0% | 12.1% | 16.8% | 12.6% | 17.9% | 18.5% | 21.1% | 12.6% | 16.2% | 19.3% |
| — | -356.0% | -621.8% | +37.7% | +55.4% | -48.4% | -75.2% | -55.8% | -39.2% | -53.0% | -52.5% | -49.9% | -34.5% | -20.4% | +0.6% | +10.4% | -4.2% | +13.2% | -16.3% | +1.0% | -5.1% | |
| Net Margin | -0.3% | -12.8% | -6.2% | 1.7% | 2.7% | -6.9% | 1.0% | 2.2% | 1.4% | 4.7% | 0.9% | 7.1% | 24.0% | 11.9% | 8.4% | 11.2% | 13.7% | 13.8% | 8.4% | 10.4% | 11.1% |
| — | -84.7% | -750.7% | -19.5% | +90.3% | -246.4% | +0.4% | -69.2% | -94.2% | -60.1% | -88.7% | -36.8% | +74.9% | -14.0% | -0.5% | +7.8% | +24.1% | -3.6% | -16.6% | +1.3% | +0.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.4% | -4.7% | -2.1% | 0.6% | 1.0% | -2.7% | 0.4% | 0.9% | 0.7% | 2.2% | 0.5% | 3.6% | 15.5% | 7.1% | 4.7% | 6.6% | 9.3% | 9.1% | 4.9% | 5.8% | 7.0% |
| — | -71.7% | -616.9% | -39.5% | +38.8% | -222.6% | -11.9% | -73.3% | -95.2% | -68.4% | -90.0% | -45.9% | +65.6% | -22.1% | -4.5% | +13.1% | +34.2% | +9.5% | -15.4% | +0.1% | -2.1% | |
| ROA | -0.1% | -1.9% | -0.9% | 0.2% | 0.4% | -0.9% | 0.1% | 0.3% | 0.2% | 0.7% | 0.1% | 1.2% | 5.1% | 2.3% | 1.5% | 2.1% | 2.8% | 2.6% | 1.4% | 1.7% | 2.2% |
| — | -101.7% | -788.9% | -21.5% | +78.4% | -237.1% | -15.1% | -74.5% | -95.5% | -70.3% | -90.3% | -44.0% | +81.7% | -12.4% | +5.0% | +21.2% | +25.5% | -6.5% | -24.1% | -8.2% | -3.9% | |
| ROIC | 4.4% | -1.7% | -1.2% | 0.8% | 2.0% | 0.6% | 0.2% | 0.6% | 1.4% | 1.3% | 1.1% | 2.0% | 3.5% | 4.6% | 3.4% | 5.1% | 6.1% | 6.9% | 3.8% | 5.1% | 7.2% |
| — | -370.6% | -635.3% | +30.6% | +46.4% | -50.9% | -79.9% | -68.7% | -61.6% | -72.6% | -67.8% | -61.2% | -41.9% | -32.4% | -10.1% | +1.0% | -15.5% | +4.5% | -29.9% | -12.0% | -7.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.73 | 0.79 | 0.67 | 0.81 | 0.81 | 1.30 | 1.14 | 1.24 | 1.31 | 1.24 | 1.01 | 0.98 | 0.98 | 0.99 | 1.03 | 1.12 | 1.21 | 1.20 | 1.17 | 1.28 |
| — | -9.3% | -39.3% | -41.5% | -34.2% | -38.6% | +4.9% | +13.1% | +26.7% | +33.8% | +25.1% | -1.6% | -13.0% | -19.0% | -16.9% | -12.5% | -12.6% | +59.4% | +46.5% | +39.6% | +37.2% | |
| Debt / EBITDA | 4.48 | — | — | 16.18 | 12.02 | 22.14 | 35.81 | 25.72 | 17.96 | 20.30 | 24.33 | 14.72 | 9.80 | 8.07 | 11.09 | 8.32 | 8.17 | 7.42 | 12.41 | 10.29 | 9.00 |
| — | — | — | -37.1% | -33.1% | +9.1% | +47.2% | +74.7% | +83.3% | +151.5% | +119.3% | +77.0% | +19.9% | +8.8% | -10.6% | -19.2% | -9.2% | +21.5% | +60.4% | +39.1% | +47.2% | |
| Current Ratio | 1.73 | 1.84 | 1.85 | 1.55 | 1.73 | 1.85 | 1.61 | 1.57 | 1.60 | 1.66 | 1.65 | 1.81 | 1.80 | 1.89 | 2.08 | 2.03 | 2.31 | 2.36 | 2.55 | 2.56 | 2.63 |
| — | -0.7% | +15.1% | -1.1% | +7.9% | +11.8% | -2.7% | -13.3% | -11.0% | -12.4% | -20.6% | -11.0% | -22.1% | -19.7% | -18.5% | -20.4% | -12.2% | +9.1% | +23.7% | +23.9% | +8.3% | |
| Quick Ratio | 0.87 | 0.90 | 0.92 | 0.72 | 0.87 | 0.91 | 0.70 | 0.74 | 0.77 | 0.73 | 0.75 | 0.91 | 0.99 | 1.04 | 1.21 | 1.22 | 1.44 | 1.49 | 1.62 | 1.72 | 1.88 |
| — | -1.1% | +30.9% | -2.0% | +13.6% | +23.9% | -6.4% | -19.0% | -22.7% | -29.3% | -38.0% | -24.9% | -30.7% | -30.3% | -25.6% | -29.2% | -23.5% | +9.1% | +25.2% | +30.0% | +20.6% | |
| Interest Coverage | 1.36 | — | — | 2.49 | 7.09 | -2.54 | 1.03 | 2.92 | 4.60 | 5.77 | 2.52 | 15.32 | 55.75 | 31.56 | 20.87 | 15.81 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BRKR stock.
Bruker Corporation's current P/E is -75.8x. The average P/E over the last 2 quarters is 257.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bruker Corporation's current operating margin is 6.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bruker Corporation's business trajectory between earnings reports.